Signant Health has announced improvements to its Randomization and Trial Supply Management (RTSM) platform for delivery of clinical supplies to patients’ homes directly.
Signant SmartSignals RTSM will enable customers to leverage additional digitally optimised trial benefits.
The enhancements to the platform enable secure, convenient, and encrypted information storage related to shipment addresses of patients, integration with depot/central pharmacy ordering systems, and reporting of courier status.
This ensures transparent and simple medication provisioning to the patient directly with complete investigator oversight.
Signant Health RTSM product management director Bart Nicholson said: “The lack of comprehensive, RTSM-driven approaches to direct-to-patient medication delivery has slowed uptake of this important aspect of trial optimisation.
“We worked closely with customers and other stakeholders to develop a solution that solves critical issues essential for a successful, technology-enabled, direct-to-patient experience.
“Simplifying processes for sites, ensuring full sponsor oversight of the medication chain of custody, and maintaining investigator dosing authority are critical components we have comprehensively addressed with this latest release.”
Additionally, the company has collaborated with courier providers for ‘last mile’ clinical supply deliveries to the homes of patients, thereby eliminating the need for manual steps.
With Signant SmartSignals RTSM, investigators and sponsors will have complete visibility of the medication chain of custody for all steps in the process.
The Signant SmartSignals RTSM-powered direct-to-patient supply management is now available and can be applied to a range of clinical trials.
Last month, Signant Health announced new advancements in its electronic Clinical Outcomes Assessment (eCOA) software, Signant SmartSignals eCOA, to address trial sponsors and contract research organisations’ requirements.
